A Phase I Randomized Clinical Trial of Candidate Human Immunodeficiency Virus type 1 Vaccine MVA.HIVA Administered to Gambian Infants

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Afolabi, Muhammed O ^a   Ndure, Jorjoh ^a   Drammeh, Abdoulie ^a   Darboe, Fatoumatta ^a   Mehedi, Shams Rony ^b   Rowland Jones, Sarah L ^c   Borthwick, Nicola ^d   Black, Antony ^d   Ambler, Gwen ^d   John Stewart, Grace C ^d   Reilly, Marie ^e   Hanke, Tomáš ^d   Flanagan, Katie L ^a  

^a Vaccinology Theme   (Gambia)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

^e NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA VACCINE; GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MVA.HIVA VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; DNA VACCINE; MVA-HIVA VACCINE;

ANTIBODY RESPONSE; ARTICLE; BIOASSAY; BODY WEIGHT DISORDER; BREAST FEEDING; BREAST MILK; CONTROLLED STUDY; COUGHING; CRYING; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERANCE; EX VIVO STUDY; EXPANDED PROGRAM ON IMMUNIZATION; FEASIBILITY STUDY; FEMALE; FEVER; GAMBIA; HEALTH PROGRAM; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; INFANT; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POOR WEIGHT GAIN; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; VACCINATION; VIRUS TRANSMISSION; VOMITING; ANTIBODY PRODUCTION; CLINICAL TRIAL; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PROCEDURES; SECONDARY IMMUNIZATION; VACCINIA VIRUS; VIROLOGY;

AIDS VACCINES; ANTIBODY FORMATION; BREAST FEEDING; FEMALE; GAMBIA; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INTERFERON-GAMMA; MALE; MILK, HUMAN; VACCINATION; VACCINES, DNA; VACCINIA VIRUS;

EID: 84886308087     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078289     Document Type: Article

References (59)

1. UNAIDS (2012) Report on the Global AIDS Epidemic 2012. Switzerland: Geneva.
2. Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, et al. (2004) Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 189: 2154-2166. doi:10.1086/420834. PubMed: 15181561.
3. Kourtis AP, Jamieson DJ, de Vincenzi I, Taylor A, Thigpen MC, et al. (2007) Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments. Am J Obstet Gynecol 197 (3 Suppl) ():: S113-S122. doi:10.1016/j.ajog.2007.10.386. PubMed: 17825642.
4. Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, et al. (2003) Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 187: 741-747. doi:10.1086/374273. PubMed: 12599047.
5. Mbori-Ngacha D, Nduati R, John G, Reilly M, Richardson B, et al. (2001) Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial. JAMA 286: 2413-2420. doi:10.1001/jama.286.19.2413. PubMed: 11712936.
6. UNAIDS (2012) Global report: UNAIDS report on the global AIDS epidemic 2012. WHO Library Cataloguing-in-Publication Data.
7. Young SL, Mbuya MN, Chantry CJ, Geubbels EP, Israel-Ballard K, et al. (2011) Current knowledge and future research on infant feeding in the context of HIV: basic, clinical, behavioral, and programmatic perspectives. Adv Nutr 2: 225-243. doi:10.3945/an.110.000224. PubMed: 22332055.
8. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF, (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10: 11-23. doi:10.1038/nri2674. PubMed: 20010788.
9. Mo H, Monard S, Pollack H, Ip J, Rochford G, et al. (1998) Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res Hum Retroviruses 14: 607-617. doi:10.1089/aid.1998.14.607. PubMed: 9591715.
10. Luzuriaga K, Sullivan JL, (2002) Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev 4: 21-26. PubMed: 11998780.
11. Richardson BA, Mbori-Ngacha D, Lavreys L, John-Stewart GC, Nduati R, et al. (2003) Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol 77: 7120-7123. doi:10.1128/JVI.77.12.7120-7123.2003. PubMed: 12768032.
12. Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, et al. (2000) Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis 181: 890-896. doi:10.1086/315298. PubMed: 10720509.
13. Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, et al. (2001) Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis 32: 801-807. doi:10.1086/319215. PubMed: 11229849.
14. McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, et al. (2001) Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis 184: 1331-1335. doi:10.1086/323994. PubMed: 11679925.
15. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671. doi:10.1086/508748. PubMed: 17109337.
16. Johnson DC, McFarland EJ, Muresan P, Fenton T, McNamara J, et al. (2005) Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis 192: 2129-2133. doi:10.1086/498163. PubMed: 16288378.
17. McFarland EJ, Johnson DC, Muresan P, Fenton T, Tomaras GD, et al. (2006) HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 20: 1481-1489. doi:10.1097/01.aids.0000237363.33994.45. PubMed: 16847402.
18. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492. PubMed: 19843557.
19. Kintu K, Andrew P, Musoke P, Richardson P, Asiimwe-Kateera B, et al. (2013) Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr 63: 1-8. doi:10.1097/QAI.0b013e3182921554. PubMed: 23221981.
20. Hicar MD, (2013) Immunotherapies to prevent mother-to-child transmission of HIV. Curr HIV Res 11: 137-143. doi:10.2174/1570162X11311020006. PubMed: 23432489.
21. Mayr A, Stickl H, Müller HK, Danner K, Singer H, (1978) [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B 167: 375-390. PubMed: 219640.
22. Im EJ, Hanke T, (2004) MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 3: S89-S97. doi:10.1586/14760584.3.1.89. PubMed: 15285708.
23. Hanke T, McMichael AJ, (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6: 951-955. doi:10.1038/79626. PubMed: 10973301.
24. Rosario M, Fulkerson J, Soneji S, Parker J, Im EJ, et al. (2010) Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J Virol 84: 7815-7821. doi:10.1128/JVI.00726-10. PubMed: 20484495.
25. Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, et al. (2010) Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J Virol 84: 5898-5908. doi:10.1128/JVI.02607-09. PubMed: 20375158.
26. Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, et al. (2003) Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84: 361-368. doi:10.1099/vir.0.18738-0. PubMed: 12560568.
27. Dorrell L, Yang H, Iversen AK, Conlon C, Suttill A, et al. (2005) Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 19: 1321-1323. doi:10.1097/01.aids.0000180104.65640.16. PubMed: 16052088.
28. Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, et al. (2006) Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80: 4705-4716. doi:10.1128/JVI.80.10.4705-4716.2006. PubMed: 16641264.
29. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, et al. (2006) Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80: 4717-4728. doi:10.1128/JVI.80.10.4717-4728.2006. PubMed: 16641265.
30. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L, (2007) Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 88: 1-12. doi:10.1099/vir.0.82493-0. PubMed: 17170430.
31. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, et al. (2004) A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85: 911-919. doi:10.1099/vir.0.19701-0. PubMed: 15039533.
32. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, et al. (2006) Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24: 417-425. doi:10.1016/j.vaccine.2005.08.041. PubMed: 16176847.
33. Dorrell L, Williams P, Suttill A, Brown D, Roberts J, et al. (2007) Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25: 3277-3283. doi:10.1016/j.vaccine.2007.01.005. PubMed: 17257714.
34. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, et al. (2008) Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26: 2788-2795. doi:10.1016/j.vaccine.2008.02.071. PubMed: 18440674.
35. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, et al. (2007) Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25: 2120-2127. doi:10.1016/j.vaccine.2006.11.016. PubMed: 17250931.
36. Miles DJ, van der Sande M, Jeffries D, Kaye S, Ojuola O, et al. (2008) Maintenance of large subpopulations of differentiated CD8 T-cells two years after cytomegalovirus infection in Gambian infants. PLOS ONE 3: e2905. doi:10.1371/journal.pone.0002905. PubMed: 18682836.
37. Hanke T, McMichael AJ, (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6: 951-955. doi:10.1038/79626. PubMed: 10973301.
38. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA, (2008) Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 335: 79-89. doi:10.1016/j.jim.2008.02.018. PubMed: 18407287.
39. Eggers M, Terletskaia-Ladwig E, Rabenau HF, Doerr HW, Diedrich S, et al. (2010) Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany. BMC Infect Dis 10: 347. doi:10.1186/1471-2334-10-347. PubMed: 21143885.
40. Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, et al. (2011) Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 3: 88ra56.
41. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, et al. (2006) A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS. Clin Trials 1: e29. doi:10.1371/journal.pctr.0010029.
42. Quintó L, Aponte JJ, Sacarlal J, Espasa M, Aide P, et al. (2006) Haematological and biochemical indices in young African children: in search of reference intervals. Trop Med Int Health 11: 1741-1748. doi:10.1111/j.1365-3156.2006.01764.x. PubMed: 17054755.
43. Adetifa IM, Hill PC, Jeffries DJ, Jackson-Sillah D, Ibanga HB, et al. (2009) Haematological values from a Gambian cohort--possible reference range for a West African population. Int J Lab Hematol 31: 615-622. doi:10.1111/j.1751-553X.2008.01087.x. PubMed: 18631172.
44. Onwukeme KE, Olomu IN, (1991) Haematologic indices in African children. Trop Geogr Med 43: 171-173. PubMed: 1750110.
45. Buchanan AM, Muro FJ, Gratz J, Crump JA, Musyoka AM, et al. (2010) Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region. Trop Med Int Health 15: 1011-1021. PubMed: 20636301.
46. Ondondo BO, Yang H, Dong T, di Gleria K, Suttill A, et al. (2006) Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol 36: 2585-2594. doi:10.1002/eji.200636508. PubMed: 17013989.
47. Winstone N, Guimarães-Walker A, Roberts J, Brown D, Loach V, et al. (2009) Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur J Immunol 39: 975-985. doi:10.1002/eji.200839167. PubMed: 19266489.
48. Yang H, Dong T, Turnbull E, Ranasinghe S, Ondondo B, et al. (2007) Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy. J Immunol 179: 597-606. PubMed: 17579081.
49. Chapman R, Chege G, Shephard E, Stutz H, Williamson AL, (2010) Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res 8: 282-298. doi:10.2174/157016210791208686. PubMed: 20353397.
50. Jacobs WR Jr., Tuckman M, Bloom BR, (1987) Introduction of foreign DNA into mycobacteria using a shuttle phasmid. Nature 327: 532-535. doi:10.1038/327532a0. PubMed: 3473289.
51. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244. doi:10.1038/nm1128. PubMed: 15502839.
52. Hopkins R, Bridgeman A, Bourne C, Mbewe-Mvula A, Sadoff JC, et al. (2011) Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 41: 3542-3552. doi:10.1002/eji.201141962. PubMed: 21932450.
53. Hopkins R, Bridgeman A, Joseph J, Gilbert SC, McShane H, et al. (2011) Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis. PLOS ONE 6: e20067. doi:10.1371/journal.pone.0020067. PubMed: 21603645.
54. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, et al. (2007) Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 81: 9408-9418. doi:10.1128/JVI.00707-07. PubMed: 17596303.
55. Joseph J, Saubi N, Pezzat E, Gatell JM, (2006) Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges. Expert Rev Vaccines 5: 827-838. doi:10.1586/14760584.5.6.827. PubMed: 17184220.
56. Saubi N, Im EJ, Fernandez-Lloris R, Gil O, Cardona PJ, et al. (2011) Newborn Mice Vaccination with BCG.HIVA + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes. Clin Dev Immunol: pp. 2011: 516219.
57. Borthwick N, Ahmed T, Ebrahimsa U, Rose A, Black A, et al. (2012). Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial. Boston, MA, USA. pp. Ppp. 04.11.
58. Hanke T, McMichael AJ, (2011) HIV-1: from escapism to conservatism. Eur J Immunol 41: 3390-3393. doi:10.1002/eji.201190072. PubMed: 22125004.
59. Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLOS ONE 2: e984. doi:10.1371/journal.pone.0000984. PubMed: 17912361.